Radiopharmaceutical for detecting PSMA - positive metastatic colon cancer: Matched-pair comparison of 18F-BF3-Cy3-ACUPA and 68Ga-PSMA PET/MRI.
Omer ArasÇetin DemirdağHarikrishna KommidiRichard TingHaluk Burçak SaymanPublished in: Nuclear medicine review. Central & Eastern Europe (2022)
Prostate-specific membrane antigen (PSMA) - based radiopharmaceuticals are promising for the evaluation of PSMA-positive non-prostate cancers. In this case study, 18F-BF3-Cy3-ACUPA and 68Ga-PSMA positron emission tomography/magnetic resonance imaging (PET/MRI) were compared in a patient with metastatic colon cancer. Both 18F-BF3-Cy3-ACUPA and 68Ga-PSMA PET/MRI showed biopsy-proven metastatic left external iliac adenopathy, highlighting the feasibility of PSMA uptake in PET/MRI of metastatic nodal disease from colon cancer. Along with imaging evaluation, PSMA-based radiopharmaceuticals may also be used as a surrogate imaging tracer for potential theranostic applications using alpha or beta emitters in the context of PSMA-directed radiopharmaceutical therapy in advanced and progressive colorectal cancer.
Keyphrases
- pet ct
- positron emission tomography
- magnetic resonance imaging
- pet imaging
- contrast enhanced
- squamous cell carcinoma
- small cell lung cancer
- prostate cancer
- computed tomography
- high resolution
- diffusion weighted imaging
- magnetic resonance
- multiple sclerosis
- mesenchymal stem cells
- stem cells
- photodynamic therapy
- bone marrow
- case report
- climate change
- neoadjuvant chemotherapy
- young adults